전체 프로그램

ADCLimited DatastaleSeagenvedotin and the anti-HER2 t…Preclinical

Genetical Recombination (Brentuximab Vedotin, Brentuximab Vedotin (Genetical Recombination))

Untreated CD30-Positive Hodgkin's Lymphoma · Peripheral T Cell Lymphoma

#PeripheralTCellLymphoma#ADC#Preclinical#Popular#antibody-drug-conjugate+4

Trials 93Status Active

CGTStandard DatabasestaleNovartis PharmaceuticalsPhase 2

cytogenetic analysis (cytogenetic analysis)

Chronic Myeloproliferative Disorders; Leukemia · Colorectal Cancer

#ColorectalCancer#CGT#Phase2#Popular#cell-gene-therapy+5

Trials 56Status Active

CGTLimited DatastaleThe Affiliated Hospital of Xuzh…Preclinical

GLP-1 receptor agonist (GLP-1 receptor agonist)

Type 2 Diabetes Mellitus; Susceptibility, Genetic · Type 2 Diabetes Mellitus

#Type2DiabetesMellitus#CGT#Preclinical#cell-gene-therapy#CAR-T+4

Trials 31Status Recruiting

CGTLimited DatastaleFate TherapeuticsPreclinical

Genetically engineered NK cells (Genetically engineered NK cells)

Hematological Malignancy · Hematological Malignancy

#HematologicalMalignancy#CGT#Preclinical#cell-gene-therapy#CAR-T+2

Trials 17Status Discontinued

CGTLimited DatastaleTargeted Genetics CorporationPhase 2

tgAAC94 gene therapy vector (tgAAC94 gene therapy vector)

Arthritis, Rheumatoid; Arthritis, Psoriatic · Arthritis, Rheumatoid

#ArthritisRheumatoid#CGT#Phase2#cell-gene-therapy#CAR-T+4

Trials 2Status Active

CGTAAVLimited DatastaleOpus Genetics, IncPhase 2

AAV8.hLCA5 (AAV8.hLCA5)

LCA5 · LCA5

#LCA5#CGT#Phase2#cell-gene-therapy#CAR-T+2

Trials 1Status Recruiting

CGTLimited DatastaleAllorunning TherapeuticsPhase 1

BCMA/CD19-targeted allogeneic CAR-T (BCMA/CD19-targeted allogeneic CAR-T)

Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT; Newly Diagnose… · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4

Trials 1Status Recruiting

CGTLimited DatastaleShanghai Exuma Biotechnology Lt…Phase 1

C402-CD19-CAR (C402-CD19-CAR)

Diffuse Large B-cell-lymphoma; DLBCL, Nos Genetic Subtypes · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5

Trials 1Status Recruiting

AntibodyLimited DatastaleHenan Provincial People's Hospi…Preclinical

Gene evolution and molecular response under Bevacizumab treatment (Gene evolution and molecular response under Bevacizumab treatment)

Genetic Change · Genetic Change

#GeneticChange#Antibody#Preclinical#monoclonal-antibody#Henan

Trials 1Status Recruiting

CGTAAVLimited DatastaleJanssen Research & Development,…Phase 3

Genetic: AAV5-hRKp.RPGR (Genetic: AAV5-hRKp.RPGR)

X-Linked Retinitis Pigmentosa · X-Linked Retinitis Pigmentosa

#X-LinkedRetinitisPigmentosa#CGT#Phase3#cell-gene-therapy#CAR-T+2

Trials 1Status Active

CGTAAVLimited DatastaleJanssen Research & Development,…Phase 3

Genetic: AAV5-hRKp.RPGR Intermediate Dose (Genetic: AAV5-hRKp.RPGR Intermediate Dose)

X-Linked Retinitis Pigmentosa · X-Linked Retinitis Pigmentosa

#X-LinkedRetinitisPigmentosa#CGT#Phase3#cell-gene-therapy#CAR-T+2

Trials 1Status Recruiting

CGTLimited DatastaleAllotera TherapeuticsPreclinical

Genetic: WU-CART-007 (Genetic: WU-CART-007)

T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Preclinical#cell-gene-therapy#CAR-T+3

Trials 1Status Active

CGTLimited DatastaleMuscular Dystrophy AssociationPhase 1

Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort (Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort)

Muscular Dystrophies · Muscular Dystrophies

#MuscularDystrophies#CGT#Phase1#cell-gene-therapy#CAR-T+2

Trials 1Status Active

CGTLimited DatastaleOttawa Heart Institute Research…Phase 3

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Stable Coronary Artery Disease; Acute Coronary Syndrome · Stable Coronary Artery Disease

#StableCoronaryArteryDisease#CGT#Phase3#cell-gene-therapy#CAR-T+3

Trials 1Status Active

CGTLimited DatastaleTargeted Genetics CorporationPhase 3

tgAAVCF (tgAAVCF)

Cystic Fibrosis · Cystic Fibrosis

#CysticFibrosis#CGT#Phase3#cell-gene-therapy#CAR-T+2

Trials 1Status Discontinued

다음 갱신 D-5 · 마지막 9월 2일 · 방문 1,027 / 70,861

Biologic만FDA만

ADCLimited DatastaleSeagenvedotin and the anti-HER2 t…Preclinical

Genetical Recombination (Brentuximab Vedotin, Brentuximab Vedotin (Genetical Recombination))

Untreated CD30-Positive Hodgkin's Lymphoma · Peripheral T Cell Lymphoma

#PeripheralTCellLymphoma#ADC#Preclinical#Popular#antibody-drug-conjugate+4

Trials 93Status Active

CGTStandard DatabasestaleNovartis PharmaceuticalsPhase 2

cytogenetic analysis (cytogenetic analysis)

Chronic Myeloproliferative Disorders; Leukemia · Colorectal Cancer

#ColorectalCancer#CGT#Phase2#Popular#cell-gene-therapy+5

Trials 56Status Active

CGTLimited DatastaleThe Affiliated Hospital of Xuzh…Preclinical

GLP-1 receptor agonist (GLP-1 receptor agonist)

Type 2 Diabetes Mellitus; Susceptibility, Genetic · Type 2 Diabetes Mellitus

#Type2DiabetesMellitus#CGT#Preclinical#cell-gene-therapy#CAR-T+4

Trials 31Status Recruiting

CGTLimited DatastaleFate TherapeuticsPreclinical

Genetically engineered NK cells (Genetically engineered NK cells)

Hematological Malignancy · Hematological Malignancy

#HematologicalMalignancy#CGT#Preclinical#cell-gene-therapy#CAR-T+2

Trials 17Status Discontinued

CGTLimited DatastaleTargeted Genetics CorporationPhase 2

tgAAC94 gene therapy vector (tgAAC94 gene therapy vector)

Arthritis, Rheumatoid; Arthritis, Psoriatic · Arthritis, Rheumatoid

#ArthritisRheumatoid#CGT#Phase2#cell-gene-therapy#CAR-T+4

Trials 2Status Active

CGTAAVLimited DatastaleOpus Genetics, IncPhase 2

AAV8.hLCA5 (AAV8.hLCA5)

LCA5 · LCA5

#LCA5#CGT#Phase2#cell-gene-therapy#CAR-T+2

Trials 1Status Recruiting

CGTLimited DatastaleAllorunning TherapeuticsPhase 1

BCMA/CD19-targeted allogeneic CAR-T (BCMA/CD19-targeted allogeneic CAR-T)

Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT; Newly Diagnose… · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4

Trials 1Status Recruiting

CGTLimited DatastaleShanghai Exuma Biotechnology Lt…Phase 1

C402-CD19-CAR (C402-CD19-CAR)

Diffuse Large B-cell-lymphoma; DLBCL, Nos Genetic Subtypes · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5

Trials 1Status Recruiting

AntibodyLimited DatastaleHenan Provincial People's Hospi…Preclinical

Gene evolution and molecular response under Bevacizumab treatment (Gene evolution and molecular response under Bevacizumab treatment)

Genetic Change · Genetic Change

#GeneticChange#Antibody#Preclinical#monoclonal-antibody#Henan

Trials 1Status Recruiting

CGTAAVLimited DatastaleJanssen Research & Development,…Phase 3

Genetic: AAV5-hRKp.RPGR (Genetic: AAV5-hRKp.RPGR)

X-Linked Retinitis Pigmentosa · X-Linked Retinitis Pigmentosa

#X-LinkedRetinitisPigmentosa#CGT#Phase3#cell-gene-therapy#CAR-T+2

Trials 1Status Active

CGTAAVLimited DatastaleJanssen Research & Development,…Phase 3

Genetic: AAV5-hRKp.RPGR Intermediate Dose (Genetic: AAV5-hRKp.RPGR Intermediate Dose)

X-Linked Retinitis Pigmentosa · X-Linked Retinitis Pigmentosa

#X-LinkedRetinitisPigmentosa#CGT#Phase3#cell-gene-therapy#CAR-T+2

Trials 1Status Recruiting

CGTLimited DatastaleAllotera TherapeuticsPreclinical

Genetic: WU-CART-007 (Genetic: WU-CART-007)

T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Preclinical#cell-gene-therapy#CAR-T+3

Trials 1Status Active

CGTLimited DatastaleMuscular Dystrophy AssociationPhase 1

Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort (Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort)

Muscular Dystrophies · Muscular Dystrophies

#MuscularDystrophies#CGT#Phase1#cell-gene-therapy#CAR-T+2

Trials 1Status Active

CGTLimited DatastaleOttawa Heart Institute Research…Phase 3

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Stable Coronary Artery Disease; Acute Coronary Syndrome · Stable Coronary Artery Disease

#StableCoronaryArteryDisease#CGT#Phase3#cell-gene-therapy#CAR-T+3

Trials 1Status Active

CGTLimited DatastaleTargeted Genetics CorporationPhase 3

tgAAVCF (tgAAVCF)

Cystic Fibrosis · Cystic Fibrosis

#CysticFibrosis#CGT#Phase3#cell-gene-therapy#CAR-T+2

Trials 1Status Discontinued

Genetical Recombination (Brentuximab Vedotin, Brentuximab Vedotin (Genetical Recombination))

cytogenetic analysis (cytogenetic analysis)

GLP-1 receptor agonist (GLP-1 receptor agonist)

Genetically engineered NK cells (Genetically engineered NK cells)

tgAAC94 gene therapy vector (tgAAC94 gene therapy vector)

AAV8.hLCA5 (AAV8.hLCA5)

BCMA/CD19-targeted allogeneic CAR-T (BCMA/CD19-targeted allogeneic CAR-T)

C402-CD19-CAR (C402-CD19-CAR)

Gene evolution and molecular response under Bevacizumab treatment (Gene evolution and molecular response under Bevacizumab treatment)

Genetic: AAV5-hRKp.RPGR (Genetic: AAV5-hRKp.RPGR)

Genetic: AAV5-hRKp.RPGR Intermediate Dose (Genetic: AAV5-hRKp.RPGR Intermediate Dose)

Genetic: WU-CART-007 (Genetic: WU-CART-007)

Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort (Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers)

tgAAVCF (tgAAVCF)

전체 프로그램

Genetical Recombination (Brentuximab Vedotin, Brentuximab Vedotin (Genetical Recombination))

cytogenetic analysis (cytogenetic analysis)

GLP-1 receptor agonist (GLP-1 receptor agonist)

Genetically engineered NK cells (Genetically engineered NK cells)

tgAAC94 gene therapy vector (tgAAC94 gene therapy vector)

AAV8.hLCA5 (AAV8.hLCA5)

BCMA/CD19-targeted allogeneic CAR-T (BCMA/CD19-targeted allogeneic CAR-T)

C402-CD19-CAR (C402-CD19-CAR)

Gene evolution and molecular response under Bevacizumab treatment (Gene evolution and molecular response under Bevacizumab treatment)

Genetic: AAV5-hRKp.RPGR (Genetic: AAV5-hRKp.RPGR)

Genetic: AAV5-hRKp.RPGR Intermediate Dose (Genetic: AAV5-hRKp.RPGR Intermediate Dose)

Genetic: WU-CART-007 (Genetic: WU-CART-007)

Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort (Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers)

tgAAVCF (tgAAVCF)

전체 프로그램

Genetical Recombination (Brentuximab Vedotin, Brentuximab Vedotin (Genetical Recombination))

cytogenetic analysis (cytogenetic analysis)

GLP-1 receptor agonist (GLP-1 receptor agonist)

Genetically engineered NK cells (Genetically engineered NK cells)

tgAAC94 gene therapy vector (tgAAC94 gene therapy vector)

AAV8.hLCA5 (AAV8.hLCA5)

BCMA/CD19-targeted allogeneic CAR-T (BCMA/CD19-targeted allogeneic CAR-T)

C402-CD19-CAR (C402-CD19-CAR)

Gene evolution and molecular response under Bevacizumab treatment (Gene evolution and molecular response under Bevacizumab treatment)

Genetic: AAV5-hRKp.RPGR (Genetic: AAV5-hRKp.RPGR)

Genetic: AAV5-hRKp.RPGR Intermediate Dose (Genetic: AAV5-hRKp.RPGR Intermediate Dose)

Genetic: WU-CART-007 (Genetic: WU-CART-007)

Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort (Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers)

tgAAVCF (tgAAVCF)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)

Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers (Point-of-care genetic screening with subsequent prasugrel administration to CYP2C192 carriers)